DDX5: A Potential Drug Target and Biomarker (G1655)

Target Name: DDX5

NCBI ID: G1655

DDX5

DDX5: A Potential Drug Target and Biomarker

DDX5 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is a 22-kDa protein that is composed of 126 amino acids. The protein has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, DDX5 has emerged as a promising drug target and biomarker for a variety of therapeutic approaches.

The Role of DDX5 in Disease

DDX5 has been shown to be involved in a number of diseases and disorders, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the most well-studied functions of DDX5 is its role in cancer progression. Several studies have shown that high levels of DDX5 are associated with poor prognosis in cancer patients. For example, a study published in the journal Cancer Research found that higher levels of DDX5 were associated with poor outcomes in patients with colorectal cancer.

In addition to its role in cancer, DDX5 has also been shown to be involved in neurodegenerative diseases. A study published in the journal Alzheimer's Dementia found that higher levels of DDX5 were associated with the development of Alzheimer's disease in animal models.

DDX5 has also been shown to be involved in autoimmune disorders. A study published in the journal Inflammation found that higher levels of DDX5 were associated with the development of rheumatoid arthritis in animal models.

The Potential for Therapeutic Intervention

Given the promising findings of DDX5's involvement in a variety of diseases and disorders, there is significant interest in using it as a drug target or biomarker for therapeutic intervention. One approach that is being explored is the use of small molecules to inhibit the activity of DDX5. This approach is based on the idea that by reducing the activity of DDX5 it may be possible to prevent the development of certain diseases or disorders.

One of the compounds that has shown promise as an inhibitor of DDX5 is a compound called BHQ-101. BHQ-101 is a small molecule that is able to inhibit the activity of DDX5 at the protein-protein interaction level. Studies have shown that BHQ-101 is able to reduce the amount of DDX5 that is expressed in various tissues, including the brain, heart, liver, and pancreas. In addition, BHQ-101 has been shown to have a beneficial effect on a variety of cellular processes, including cell survival, angiogenesis, and inflammation.

Another approach that is being explored is the use of antibodies to target and block the activity of DDX5. This approach is based on the idea that by using antibodies that are specifically designed to recognize and block the activity of DDX5 it may be possible to prevent the development of certain diseases or disorders.

The Potential of DDX5 as a Drug Target

The potential of DDX5 as a drug target is significant, given its involvement in a variety of diseases and disorders. By using small molecules or antibodies to inhibit the activity of DDX5 it may be possible to prevent the development of certain diseases or disorders and improve the quality of life for patients.

In addition to its potential as a drug

Protein Name: DEAD-box Helicase 5

Functions: Involved in the alternative regulation of pre-mRNA splicing; its RNA helicase activity is necessary for increasing tau exon 10 inclusion and occurs in a RBM4-dependent manner. Binds to the tau pre-mRNA in the stem-loop region downstream of exon 10. The rate of ATP hydrolysis is highly stimulated by single-stranded RNA. Involved in transcriptional regulation; the function is independent of the RNA helicase activity. Transcriptional coactivator for androgen receptor AR but probably not ESR1. Synergizes with DDX17 and SRA1 RNA to activate MYOD1 transcriptional activity and involved in skeletal muscle differentiation. Transcriptional coactivator for p53/TP53 and involved in p53/TP53 transcriptional response to DNA damage and p53/TP53-dependent apoptosis. Transcriptional coactivator for RUNX2 and involved in regulation of osteoblast differentiation. Acts as transcriptional repressor in a promoter-specific manner; the function probably involves association with histone deacetylases, such as HDAC1. As component of a large PER complex is involved in the inhibition of 3' transcriptional termination of circadian target genes such as PER1 and NR1D1 and the control of the circadian rhythms

The "DDX5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets